secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-06-18T13:02:06+00:00
Accession:  0001213900-26-069902
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki
--------------------------------------------------------------------------------

- Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
- If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).
- Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).
- Company to present at BIO International Convention June 22-25, 2026, seeking partnerships.
- Kawasaki disease is leading cause of acquired heart disease in children; up to 25% untreated develop CAAs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/0001213900-26-069902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026069902/ea0295234-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-069902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer